Bremelanotide (PT-141)
Boosts sexual desire in both sexes
- Increased Libido (men and women)
- Erectile Dysfunction
Do not use in patients with uncontrolled hypertension or significant cardiovascular disease Nausea is common and may be dose-limiting in some individuals Long-term safety data is limited - most trials were short-duration
Mechanism of Action
Bremelanotide (PT-141) is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors, particularly MC3R and MC4R, located in the central nervous system. Unlike PDE-5 inhibitors that work through peripheral vascular mechanisms, PT-141 activates neurons in the hypothalamus to initiate sexual arousal responses through direct CNS stimulation. Key Pathways: Melanocortin receptor (MC3R/MC4R) activation in hypothalamus, Central nervous system dopaminergic and oxytocinergic signaling, Hypothalamic-mediated autonomic sexual response pathways Because PT-141 works through central nervous system pathways rather than directly on blood vessels, it addresses sexual dysfunction at the level of desire and arousal initiation. This mechanism explains why it can be effective in patients who do not respond to PDE-5 inhibitors like sildenafil, and why it shows efficacy for both male erectile dysfunction and female sexual desire disorders.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Bremelanotide (PT-141) protocols — frequency, timing, cycle length, reconstitution & research
- Nausea
- Flushing
- Headache
- Nasal congestion
- Blood pressure changes
- Increased skin pigmentation